Hereditary spherocytosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(4 intermediate revisions by one other user not shown)
Line 10: Line 10:
'''For patient information click [[Hereditary spherocytosis (patient information)|here]]'''
'''For patient information click [[Hereditary spherocytosis (patient information)|here]]'''


{{CMG}} {{ZAS}}
{{CMG}}; {{AE}} {{ZAS}}


==[[Hereditary spherocytosis overview|Overview]]==
==[[Hereditary spherocytosis overview|Overview]]==
'''Hereditary spherocytosis''' is a genetically-transmitted form of [[spherocytosis]], an auto-[[Hemolysis|hemolytic]] [[anemia]] characterized by the production of red blood cells that are sphere-shaped rather than donut-shaped, and therefore more prone to [[hemolysis]].


== [[hereditary spherocytosis historical perspective|Historical Perspective]] ==
== [[hereditary spherocytosis historical perspective|Historical Perspective]] ==
Line 40: Line 39:


== [[hereditary spherocytosis laboratory findings|Laboratory Findings]] ==
== [[hereditary spherocytosis laboratory findings|Laboratory Findings]] ==
== [[hereditary spherocytosis chest x ray|Chest X ray]] ==
== [[hereditary spherocytosis CT|CT]] ==
== [[hereditary spherocytosis MRI|MRI]] ==
== [[hereditary spherocytosis echocardiography or ultrasound| Echocardiography or Ultrasound]] ==
== [[hereditary spherocytosis other imaging findings|Other Imaging Findings]] ==
== [[hereditary spherocytosis other diagnostic studies|Other Diagnostic Studies]] ==


== [[hereditary spherocytosis medical therapy|Treatment]] ==
== [[hereditary spherocytosis medical therapy|Treatment]] ==
Line 48: Line 59:


==[[hereditary spherocytosis primary prevention|Primary Prevention]] ==
==[[hereditary spherocytosis primary prevention|Primary Prevention]] ==
* The administration of vaccines (pneumococcal, haemophilus influenzae type b, meningococcal group C and influenza) is indicated 2 to 3 weeks before splenectomy.<ref>{{Cite journal
| author = [[Sayeeda Huq]], [[Mark A. C. Pietroni]], [[Hafizur Rahman]] & [[Mohammad Tariqul Alam]]
| title = Hereditary spherocytosis
| journal = [[Journal of health, population, and nutrition]]
| volume = 28
| issue = 1
| pages = 107–109
| year = 2010
| month = February
| pmid = 20214092
}}</ref>
* Postsplenectomy patients should also be given 1mg of folic acid daily for preventing secondary folic acid deficiency and oral penicillin (penicillin V) for preventing secondary infection until reaching adulthood.


== [[hereditary spherocytosis secondary prevention|Secondary Prevention]]==
== [[hereditary spherocytosis secondary prevention|Secondary Prevention]]==
== [[hereditary spherocytosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] ==
== [[hereditary spherocytosis future or investigational therapies|Future or Investigational Therapies]] ==


== [[Hereditary spherocytosis case study one|Case Studies]] ==
== [[Hereditary spherocytosis case study one|Case Studies]] ==

Latest revision as of 20:28, 10 December 2018

Template:DiseaseDisorder infobox

Hereditary spherocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary spherocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary spherocytosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary spherocytosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary spherocytosis

CDC on Hereditary spherocytosis

Hereditary spherocytosis in the news

Blogs on Hereditary spherocytosis

Directions to Hospitals Treating Hereditary spherocytosis

Risk calculators and risk factors for Hereditary spherocytosis

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary Spherocytosis from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

Template:Otheruses4

External links

References

he:ספרוציטוזיס תורשתי sr:Сфероцитоза

Template:WikiDoc Sources